| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medicare | 10 | 2020 | 612 | 2.130 |
Why?
|
| Population Health | 3 | 2024 | 17 | 1.860 |
Why?
|
| Preventive Health Services | 3 | 2016 | 75 | 1.430 |
Why?
|
| Medicaid | 4 | 2018 | 362 | 1.250 |
Why?
|
| Opiate Substitution Treatment | 2 | 2020 | 206 | 1.110 |
Why?
|
| Health Care Reform | 4 | 2015 | 87 | 1.070 |
Why?
|
| Reimbursement Mechanisms | 2 | 2015 | 40 | 0.950 |
Why?
|
| Opioid-Related Disorders | 3 | 2020 | 507 | 0.820 |
Why?
|
| Cardiovascular Diseases | 5 | 2018 | 834 | 0.790 |
Why?
|
| Quality of Health Care | 3 | 2016 | 519 | 0.790 |
Why?
|
| United States | 21 | 2024 | 7828 | 0.780 |
Why?
|
| Behavior Therapy | 2 | 2020 | 167 | 0.730 |
Why?
|
| Motivation | 1 | 2024 | 284 | 0.710 |
Why?
|
| Analgesics, Opioid | 3 | 2020 | 536 | 0.670 |
Why?
|
| Physician's Role | 3 | 2016 | 124 | 0.670 |
Why?
|
| Accountable Care Organizations | 3 | 2016 | 67 | 0.640 |
Why?
|
| Critical Pathways | 1 | 2020 | 32 | 0.640 |
Why?
|
| Delayed-Action Preparations | 1 | 2020 | 114 | 0.630 |
Why?
|
| Inappropriate Prescribing | 1 | 2020 | 66 | 0.620 |
Why?
|
| Health Promotion | 1 | 2024 | 497 | 0.620 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2020 | 104 | 0.610 |
Why?
|
| Drug Overdose | 1 | 2020 | 131 | 0.560 |
Why?
|
| Machine Learning | 1 | 2019 | 177 | 0.550 |
Why?
|
| Chronic Pain | 1 | 2020 | 154 | 0.540 |
Why?
|
| Fee-for-Service Plans | 2 | 2015 | 69 | 0.530 |
Why?
|
| Public Policy | 1 | 2016 | 41 | 0.500 |
Why?
|
| Dementia | 1 | 2019 | 260 | 0.490 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2020 | 712 | 0.480 |
Why?
|
| Career Choice | 1 | 2016 | 131 | 0.460 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 331 | 0.460 |
Why?
|
| Government Regulation | 1 | 2015 | 41 | 0.460 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2016 | 157 | 0.460 |
Why?
|
| Humans | 35 | 2024 | 63319 | 0.450 |
Why?
|
| Organizational Innovation | 1 | 2015 | 82 | 0.450 |
Why?
|
| Relative Value Scales | 1 | 2014 | 15 | 0.430 |
Why?
|
| Medical Oncology | 1 | 2014 | 66 | 0.430 |
Why?
|
| Social Determinants of Health | 1 | 2016 | 131 | 0.410 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 350 | 0.410 |
Why?
|
| Folate Receptors, GPI-Anchored | 1 | 2012 | 2 | 0.390 |
Why?
|
| Folic Acid | 1 | 2012 | 41 | 0.380 |
Why?
|
| Flecainide | 1 | 2012 | 3 | 0.380 |
Why?
|
| Health Services Accessibility | 2 | 2018 | 564 | 0.380 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2012 | 30 | 0.380 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2012 | 43 | 0.370 |
Why?
|
| Autoantibodies | 1 | 2012 | 182 | 0.360 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 254 | 0.360 |
Why?
|
| Heart Defects, Congenital | 1 | 2012 | 102 | 0.360 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2012 | 152 | 0.350 |
Why?
|
| Blood Banks | 1 | 2010 | 9 | 0.340 |
Why?
|
| Anecdotes as Topic | 1 | 2010 | 10 | 0.340 |
Why?
|
| Pregnancy Outcome | 1 | 2012 | 194 | 0.330 |
Why?
|
| Chagas Disease | 1 | 2010 | 36 | 0.330 |
Why?
|
| Trypanosoma cruzi | 1 | 2010 | 52 | 0.330 |
Why?
|
| Adult | 11 | 2020 | 16796 | 0.320 |
Why?
|
| Heart | 1 | 2011 | 281 | 0.310 |
Why?
|
| Methadone | 2 | 2020 | 134 | 0.310 |
Why?
|
| Heart Diseases | 1 | 2011 | 217 | 0.300 |
Why?
|
| Adolescent | 6 | 2020 | 6247 | 0.300 |
Why?
|
| Female | 15 | 2020 | 32812 | 0.290 |
Why?
|
| Physicians | 1 | 2014 | 470 | 0.290 |
Why?
|
| Disorders of Sex Development | 1 | 2008 | 11 | 0.280 |
Why?
|
| Retrospective Studies | 6 | 2020 | 6642 | 0.280 |
Why?
|
| Health Care Costs | 3 | 2020 | 210 | 0.280 |
Why?
|
| Heart Ventricles | 2 | 2006 | 262 | 0.270 |
Why?
|
| Preimplantation Diagnosis | 1 | 2006 | 5 | 0.260 |
Why?
|
| Buprenorphine | 2 | 2020 | 192 | 0.260 |
Why?
|
| Young Adult | 6 | 2020 | 4687 | 0.260 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2006 | 38 | 0.260 |
Why?
|
| Pulmonary Atresia | 1 | 2006 | 2 | 0.250 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2006 | 7 | 0.250 |
Why?
|
| Reproduction | 1 | 2006 | 92 | 0.250 |
Why?
|
| Male | 12 | 2020 | 29840 | 0.240 |
Why?
|
| Exercise Tolerance | 1 | 2006 | 79 | 0.240 |
Why?
|
| Empathy | 1 | 2006 | 67 | 0.240 |
Why?
|
| United States Indian Health Service | 1 | 2005 | 3 | 0.240 |
Why?
|
| Health Expenditures | 2 | 2018 | 122 | 0.240 |
Why?
|
| Reimbursement, Incentive | 2 | 2016 | 29 | 0.240 |
Why?
|
| Computers | 1 | 2005 | 49 | 0.230 |
Why?
|
| Mass Screening | 1 | 2010 | 690 | 0.230 |
Why?
|
| Middle Aged | 7 | 2020 | 17562 | 0.220 |
Why?
|
| Cohort Studies | 2 | 2020 | 2569 | 0.210 |
Why?
|
| Community Health Services | 1 | 2005 | 128 | 0.210 |
Why?
|
| Health Education | 1 | 2005 | 189 | 0.210 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 5449 | 0.200 |
Why?
|
| Physician-Patient Relations | 1 | 2006 | 419 | 0.190 |
Why?
|
| Hospitalization | 2 | 2020 | 1359 | 0.190 |
Why?
|
| Fetal Diseases | 2 | 2012 | 21 | 0.190 |
Why?
|
| Incidence | 2 | 2019 | 1376 | 0.190 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 266 | 0.190 |
Why?
|
| Leadership | 2 | 2014 | 206 | 0.190 |
Why?
|
| Algorithms | 2 | 2019 | 999 | 0.190 |
Why?
|
| Aged | 5 | 2020 | 14400 | 0.180 |
Why?
|
| Infant, Newborn | 3 | 2020 | 1356 | 0.180 |
Why?
|
| Gestational Age | 2 | 2012 | 189 | 0.180 |
Why?
|
| Parents | 1 | 2005 | 392 | 0.170 |
Why?
|
| New Mexico | 2 | 2014 | 9 | 0.170 |
Why?
|
| Drug Tolerance | 1 | 2020 | 33 | 0.160 |
Why?
|
| Comparative Effectiveness Research | 1 | 2020 | 46 | 0.160 |
Why?
|
| Naltrexone | 1 | 2020 | 89 | 0.160 |
Why?
|
| Child | 3 | 2020 | 4531 | 0.160 |
Why?
|
| Datasets as Topic | 1 | 2019 | 27 | 0.160 |
Why?
|
| Infant | 2 | 2020 | 1650 | 0.160 |
Why?
|
| Physical Therapy Modalities | 1 | 2019 | 47 | 0.160 |
Why?
|
| Treatment Outcome | 4 | 2020 | 5664 | 0.150 |
Why?
|
| Pyridones | 1 | 2019 | 40 | 0.150 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 136 | 0.150 |
Why?
|
| Indoles | 1 | 2019 | 110 | 0.150 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 1255 | 0.150 |
Why?
|
| Low Back Pain | 1 | 2019 | 114 | 0.140 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2018 | 19 | 0.140 |
Why?
|
| Mortality | 1 | 2019 | 160 | 0.140 |
Why?
|
| Long-Acting Reversible Contraception | 1 | 2018 | 3 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 168 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2020 | 311 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 729 | 0.140 |
Why?
|
| Pregnancy, Unplanned | 1 | 2018 | 21 | 0.140 |
Why?
|
| Family Planning Services | 1 | 2018 | 21 | 0.140 |
Why?
|
| Pregnancy | 3 | 2018 | 2335 | 0.140 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 159 | 0.130 |
Why?
|
| Longevity | 1 | 2018 | 113 | 0.130 |
Why?
|
| Patient Care | 1 | 2017 | 80 | 0.130 |
Why?
|
| Weight Reduction Programs | 1 | 2017 | 57 | 0.130 |
Why?
|
| Curriculum | 2 | 2016 | 596 | 0.130 |
Why?
|
| Organizational Objectives | 1 | 2016 | 59 | 0.130 |
Why?
|
| Policy Making | 1 | 2016 | 47 | 0.130 |
Why?
|
| Case-Control Studies | 2 | 2012 | 1120 | 0.120 |
Why?
|
| Health Policy | 1 | 2018 | 192 | 0.120 |
Why?
|
| Age Factors | 1 | 2020 | 1558 | 0.120 |
Why?
|
| Prevalence | 1 | 2020 | 1378 | 0.120 |
Why?
|
| Cost Savings | 1 | 2016 | 54 | 0.120 |
Why?
|
| Schools, Medical | 1 | 2016 | 145 | 0.120 |
Why?
|
| Value-Based Purchasing | 1 | 2015 | 8 | 0.120 |
Why?
|
| Primary Prevention | 1 | 2016 | 136 | 0.120 |
Why?
|
| Surveys and Questionnaires | 3 | 2010 | 2676 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2018 | 267 | 0.120 |
Why?
|
| Prognosis | 2 | 2012 | 1747 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 121 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2020 | 1995 | 0.110 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 209 | 0.110 |
Why?
|
| Legislation as Topic | 1 | 2014 | 12 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 2457 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 734 | 0.100 |
Why?
|
| Neural Tube Defects | 1 | 2012 | 27 | 0.100 |
Why?
|
| Immunoglobulin M | 1 | 2012 | 115 | 0.100 |
Why?
|
| Digoxin | 1 | 2012 | 22 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2015 | 753 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 255 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 214 | 0.090 |
Why?
|
| Reference Values | 1 | 2012 | 335 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 298 | 0.090 |
Why?
|
| Echocardiography, Doppler | 1 | 2012 | 133 | 0.090 |
Why?
|
| Electric Countershock | 1 | 2012 | 101 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2012 | 369 | 0.090 |
Why?
|
| Blood Donors | 1 | 2010 | 23 | 0.080 |
Why?
|
| Mexico | 1 | 2010 | 39 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 459 | 0.080 |
Why?
|
| Exercise | 1 | 2017 | 940 | 0.080 |
Why?
|
| Incidental Findings | 1 | 2010 | 44 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 435 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 860 | 0.080 |
Why?
|
| Professional Competence | 1 | 2010 | 93 | 0.080 |
Why?
|
| Obesity | 1 | 2017 | 1232 | 0.080 |
Why?
|
| Myocardial Infarction | 1 | 2016 | 913 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1146 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2016 | 2077 | 0.080 |
Why?
|
| Blood Transfusion | 1 | 2010 | 161 | 0.080 |
Why?
|
| Nurses | 1 | 2010 | 108 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 311 | 0.080 |
Why?
|
| Genitalia | 1 | 2008 | 9 | 0.070 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 2008 | 5 | 0.070 |
Why?
|
| Circumcision, Male | 1 | 2008 | 10 | 0.070 |
Why?
|
| Stroke | 1 | 2016 | 1192 | 0.070 |
Why?
|
| Gender Identity | 1 | 2008 | 67 | 0.070 |
Why?
|
| Neoplasms | 1 | 2017 | 1361 | 0.070 |
Why?
|
| Dwarfism | 1 | 2006 | 15 | 0.070 |
Why?
|
| Donor Selection | 1 | 2006 | 17 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 1542 | 0.070 |
Why?
|
| Embryo Transfer | 1 | 2006 | 25 | 0.070 |
Why?
|
| Homosexuality, Female | 1 | 2006 | 21 | 0.060 |
Why?
|
| Hydrocortisone | 1 | 2008 | 193 | 0.060 |
Why?
|
| Sex Characteristics | 1 | 2008 | 203 | 0.060 |
Why?
|
| Deafness | 1 | 2006 | 37 | 0.060 |
Why?
|
| Choice Behavior | 1 | 2006 | 83 | 0.060 |
Why?
|
| American Heart Association | 2 | 2016 | 126 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 762 | 0.060 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2004 | 3 | 0.060 |
Why?
|
| Risk Factors | 2 | 2016 | 5345 | 0.060 |
Why?
|
| Exercise Test | 1 | 2006 | 252 | 0.060 |
Why?
|
| Aneurysm, False | 1 | 2004 | 50 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2004 | 95 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2006 | 555 | 0.050 |
Why?
|
| Plants, Medicinal | 1 | 2002 | 61 | 0.050 |
Why?
|
| Education, Distance | 1 | 2002 | 34 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2002 | 96 | 0.050 |
Why?
|
| Communication | 1 | 2006 | 571 | 0.040 |
Why?
|
| Embolization, Therapeutic | 1 | 2004 | 319 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2002 | 234 | 0.040 |
Why?
|
| Internet | 1 | 2002 | 469 | 0.040 |
Why?
|
| Propensity Score | 1 | 2019 | 160 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2006 | 3285 | 0.040 |
Why?
|
| Health Personnel | 1 | 2002 | 367 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 221 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 187 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2018 | 78 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 205 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2004 | 1306 | 0.030 |
Why?
|
| Tobacco Use Cessation | 1 | 2016 | 29 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 174 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 377 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1274 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 422 | 0.030 |
Why?
|
| Cancer Survivors | 1 | 2017 | 115 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2015 | 102 | 0.030 |
Why?
|
| Aspirin | 1 | 2016 | 171 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 479 | 0.030 |
Why?
|
| Cardiology | 1 | 2016 | 167 | 0.030 |
Why?
|
| Cost Control | 1 | 2014 | 24 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 216 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 769 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2016 | 509 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2019 | 690 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 310 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 1225 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 2571 | 0.020 |
Why?
|
| Prosthesis-Related Infections | 1 | 2004 | 34 | 0.010 |
Why?
|
| Abscess | 1 | 2004 | 79 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 2004 | 129 | 0.010 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2004 | 224 | 0.010 |
Why?
|
| Radiography | 1 | 2004 | 548 | 0.010 |
Why?
|
| Palliative Care | 1 | 2004 | 229 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2002 | 161 | 0.010 |
Why?
|
| Educational Measurement | 1 | 2002 | 217 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2002 | 568 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2002 | 487 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 595 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2002 | 725 | 0.010 |
Why?
|